Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
NCT ID: NCT00375570
Last Updated: 2008-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
254 participants
INTERVENTIONAL
2006-10-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
NCT00735761
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
NCT00361881
Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant
NCT00697567
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
NCT00878072
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
NCT03595995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ME-609
ME-609
Topical treatment 5 times daily for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ME-609
Topical treatment 5 times daily for 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of recurrent herpes labialis with at two recurrences during the last twelve months
Exclusion Criteria
* Significant skin condition that occur in the area of herpes recurrences
* Nursing or/and pregnancy
* Immunosupressed state due to underlying disease (e.g. HIV infection or concomitant treatment (e.g. cancer chemotherapy)
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medivir
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medivir AB
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anders Strand, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Sciences, Dermatology and Venereology University Hospital, Uppsala, Sweden
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
609-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.